JavaScript is disabled. Please enable to continue!
Mobile search icon
Eurofins >> About Us >> Eurofins Fact Sheet

Eurofins Fact Sheet

Sidebar Image

Company Overview

Eurofins Scientific is an international life sciences company which provides a unique range of analytical testing services to clients across multiple industries. The Group believes it is the world leader in food, environment, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and for supporting clinical studies. In addition, Eurofins is one of the leading global emerging players in specialty clinical diagnostic testing.

Short History

Eurofins Scientific was founded in 1987 with 4 employees to market the SNIF-NMR™ technology, a patented analytical method used to verify the origin and purity of several types of food and beverages and identify sophisticated fraud not detectable by other methods.

Today the Eurofins Group is a leading provider of analytical services with:

  • an international network of more than 800 laboratories across 47 countries in Europe, North and South America and Asia-Pacific
  • about 45,000 staff
  • a portfolio of over 200,000 validated analytical methods
  • more than 400 million tests performed each year to establish the safety, identity, composition, authenticity, origin, traceability, and purity of biological substances and products, as well as carry out human diagnostic services.

Eurofins is one of the fastest growing listed European companies. Since its IPO on the French stock exchange in 1997, Eurofins’ sales have increased by 35% each year (in compound average) to over EUR 3.7 billion in 2018.

Between the Initial Public Offering on 24 October 1997 (€1.83) and 28 June 2019 (€389.00), Eurofins’ share price has multiplied by 213x, an annual average increase of 28% (against 4% for the SBF 120, 3% for the CAC 40 and 6% for the S&P 500 over the same period).

Recent Developments

As part of its (2015 – 2020) global expansion programme Eurofins is investing massively to develop the most comprehensive portfolio of analytical methods and the most modern, state-of-the-art laboratory network in its chosen markets. The Group’s objective is to provide best-in-class analytical services in the most efficient manner in an increasing number of countries. Having consistently invested at higher rate than any of its large peers in the testing industry, Eurofins has built a very modern, streamlined network of laboratories capable of providing a unique range of high quality analyses at a reasonable cost. In 2018 alone, the Group added another 64,000m2 of world class laboratory surface to its network, and plans another 135,000m2 additional capacity between 2019 and 2020 to bring the surface of its facilities to about 1,400,000m2. In addition Eurofins is developing and deploying advanced IT solutions to manage its laboratories and the very large amounts of data it generates for its clients.

Over the years, Eurofins has developed many new analytical testing methods and has participated in, or led several R&D projects to find better ways to analyse food, the environment, and pharmaceutical products. More recently, the Group has also started to leverage its long standing genomics expertise in the area of specialty clinical diagnostics testing to provide new human diagnostic capabilities. In 2018 and H1 2019 Eurofins continued to make very good progress towards its operational objectives of building an unmatched state-of-the-art global laboratory infrastructure in its markets. Thanks to this and continued strong organic growth, in 2018 Eurofins has again achieved results in-line with its recently-upgraded objectives.

In 2018 Eurofins grew 27%, entered 3 new countries, opened 15 new start-up laboratories and welcomed over 10,000 new staff members.

Future Plans

Eurofins is committed to supporting its clients’ objectives of ensuring that their products reach the best possible quality and safety levels in all markets in which they operate and supporting medical practitioners and patients with innovative diagnostic services. The Group intends to continue to develop and acquire the most comprehensive range of state-of-the-art analytical technologies as well as expand its geographical reach in order to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities and healthcare practitioners around the world.

Contact and Addresses

Florian Heupel, Group Marketing 
23, Val Fleuri,
L-1526, Luxembourg
Tel +352 261 85 31

Investor Relations 
Avenue Herrmann Debroux 48
B- 1160 Brussels – Belgium
Tel +32 2 766 1620